What is Drugs Made In America Acquisition II EV-to-EBIT?
Drugs Made In America Acquisition IIDMII 15 EV-to-EBIT is -478.77 as of Jul. 11, 2026. GuruFocus rates DMII with a GF Score™ of 15/100. The stock has 1 warning sign investors should review. Among 158 Diversified Financial Services companies, Drugs Made In America Acquisition II ranks worse than 632910.76% on this metric.
Drugs Made In America Acquisition II (NAS:DMII) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Drugs Made In America Acquisition II's Enterprise Value for the quarter that ended in Mar. 2026 was $635.19 Mil.
Drugs Made In America Acquisition II's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.34 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Drugs Made In America Acquisition II EV-to-EBIT Related Terms
Drugs Made In America Acquisition II EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Drugs Made In America Acquisition II EV-to-EBIT Chart
Drugs Made In America Acquisition II Annual Data
Trend
Dec24
Dec25
EV-to-EBIT
0.00
-485.10
Drugs Made In America Acquisition II Quarterly Data
For the Shell Companies subindustry, Drugs Made In America Acquisition II's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Drugs Made In America Acquisition II EV-to-EBIT vs Diversified Financial Services Industry
For the Diversified Financial Services industry and Financial Services sector, Drugs Made In America Acquisition II's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Drugs Made In America Acquisition II's EV-to-EBIT falls into.
Drugs Made In America Acquisition II's current Enterprise Value is $643.47 Mil.
Drugs Made In America Acquisition II's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.34 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Drugs Made In America Acquisition II (DMII) has a EV-to-EBIT of -478.77 as of Jul. 11, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Drugs Made In America Acquisition II and its competitors. According to the industry distribution chart, Drugs Made In America Acquisition II ranks #999999 out of 158 companies in the Diversified Financial Services industry.
Is Drugs Made In America Acquisition II's EV-to-EBIT too high?
Drugs Made In America Acquisition II's current EV-to-EBIT is -478.77. Based on the distribution chart, Drugs Made In America Acquisition II ranks #999999 out of 158 companies in the Diversified Financial Services industry, which is in the bottom quartile relative to peers. Overall, Drugs Made In America Acquisition II has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Drugs Made In America Acquisition II's EV-to-EBIT compare to BCSS and EVAC?
According to the Diversified Financial Services industry distribution chart, Drugs Made In America Acquisition II ranks #999999 out of 158 companies for EV-to-EBIT. This places Drugs Made In America Acquisition II in the lower half of its industry. The industry median EV-to-EBIT is 4.39. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Diversified Financial Services company?
The median EV-to-EBIT among Diversified Financial Services companies is 4.39, based on 158 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Drugs Made In America Acquisition II and its competitors. For the Diversified Financial Services industry, the median EV-to-EBIT is 4.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Drugs Made In America Acquisition II's current EV-to-EBIT is -478.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Drugs Made In America Acquisition II stock overvalued right now?
Drugs Made In America Acquisition II (DMII) has a current EV-to-EBIT of -478.77. The current EV-to-EBIT is -478.77. Drugs Made In America Acquisition II's overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Drugs Made In America Acquisition II (DMII), the current EV-to-EBIT is -478.77 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Drugs Made In America Acquisition II Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DMII has been successfully added to your 